← Human Trials & Peer-Reviewed Studies
Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I
Plain-language guide to PMID 7564346 (1995): double-blind randomized controlled trial study of Angiotensin II in 16 subjects.
Key Facts
- PMID
- 7564346
- Journal
- Journal of cardiovascular pharmacology
- Year
- 1995
- Study type
- Randomized Controlled Trial
- Authors
- Inglessis N et al. (8 authors)
- DOI
- 10.1097/00005344-199506000-00019
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Angiotensin II.
The researchers assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor antagonist, on the pressor action of exogenous ANG I in healthy male volunteers maintained on an unrestricted sodium intake and compared it with that of enalapril.
No drug-related side effect was observed.
Who Took Part
The study group was 16 subjects.
By PubMed's age tags, the people studied were adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
Neither the subjects nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.
What Was Measured
The researchers assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor antagonist, on the pressor action of exogenous ANG I in healthy male volunteers maintained on an unrestricted sodium intake and compared it with that of enalapril.
PubMed files the paper under topics including Aldosterone, Analysis of Variance, Angiotensin I, Angiotensin II, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors and Blood Pressure.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 16 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1995 (Journal of cardiovascular pharmacology), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.